Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real Life Study Assessing Long Term Outcomes and Predictive Factors of Response to Biologicals in Patients With Severe CRSwNP and/or Severe Allergic and/or Eosinophilic Asthma

Next Previous
Trial Profile

Real Life Study Assessing Long Term Outcomes and Predictive Factors of Response to Biologicals in Patients With Severe CRSwNP and/or Severe Allergic and/or Eosinophilic Asthma

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mepolizumab (Primary) ; Dupilumab; Omalizumab
  • Indications Allergic asthma; Nasal polyps; Rhinosinusitis
  • Focus Therapeutic Use
  • Acronyms NASUMAB

Most Recent Events

  • 11 Apr 2024 Planned End Date changed from 1 Sep 2024 to 31 Dec 2030.
  • 11 Apr 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2030.
  • 14 Jul 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top